Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Eur J Cancer
; 210: 114298, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-39304280
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
ErbB Receptors
/
Bevacizumab
Limits:
Adult
/
Humans
Language:
En
Journal:
Eur J Cancer
Year:
2024
Document type:
Article
Country of publication:
Reino Unido